Search
drug interaction(s) of SGLT-2 inhititor (flozin) in combination with GLP1-agonist
Drug interactions:
- GLP-1 agonists (incretin mimetics) & SGLT-2 inhititor (flozin) have additive benefits for cardiovascular disease & diabetic nephropathy [1]
- robust improvements in cardiac & renal outcomes with SGLT-2 inhibitors, independent of GLP-1 agonist use [2]
Properties
DRUGS: GLP-1 receptor agonist
SGLT-2 inhibitor
References
- Simms-Williams N et al.
Effect of combination treatment with glucagon-like peptide-1 receptor agonists
and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and
serious renal events: Population based cohort study.
BMJ 2024 Apr 25; 385:e078242.
PMID: 38663919 PMCID: PMC11043905 Free PMC article
https://www.bmj.com/content/385/bmj-2023-078242
- Apperloo EM, Neuen BL, Fletcher RA et al.
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1
receptor agonists: A SMART-C collaborative meta-analysis of randomised controlled
trials.
Lancet Diabetes Endocrinol 2024 Aug; 12:545-557.
PMID: 38991584
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00155-4/abstract
- Escobar Cervantes C.
SGLT2 inhibitors and GLP-1 receptor agonists: The definitive combination?
Lancet Diabetes Endocrinol 2024 Aug; 12:507.
PMID: 38991583
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00183-9/abstract